Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates

Patent metadata

Field	Value
Publication number	US-10925936-B2
Application number	US-201515507443-A
Country	US
Kind code	B2
Filing date	Sep 2, 2015
Priority date	Sep 3, 2014
Publication date	Feb 23, 2021
Grant date	Feb 23, 2021

Abstract

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

First claim

The invention claimed is:

1. A vaccine pharmaceutical composition for inducing cellular immunity, comprising:
an antigen;
a first cellular immunity induction promoter that is a bisphosphonate; and
a second cellular immunity induction promoter that is a helper peptide selected from the group consisting of Peptide-25, Peptide-25B, and PADRE.

2. The vaccine pharmaceutical composition according to claim 1 , wherein the first cellular immunity induction promoter that is a bisphosphonate is at least one selected from the group consisting of etidronate, clodronate, tiludronate, pamidronate, alendronate, ibandronate, neridronate, zoledronate, risedronate, and minodronate.

3. The vaccine pharmaceutical composition according to claim 2 , further comprising at least one of an antioxidant and an anti-inflammatory drug.

4. The vaccine pharmaceutical composition according to claim 3 , wherein the vaccine pharmaceutical composition comprises at least one antioxidant selected from the group consisting of sodium nitrite, ascorbic acid, sodium hydrogen sulfite, cysteine hydrochloride, citric acid hydrate, dibutylhydroxytoluene, soybean lecithin, tocopherol, sodium pyrosulfite, dibutylhydroxyanisole, 1,3-butylene glycol, benzotriazole, propyl gallate, and 2-mercaptobenzimidazole.

5. The vaccine pharmaceutical composition according to claim 3 , wherein the vaccine pharmaceutical composition comprises at least one anti-inflammatory drug selected from the group consisting of polyphenols, alkaloids, and phospholipase A2 inhibitors.

6. The vaccine pharmaceutical composition according to claim 3 , wherein the vaccine pharmaceutical composition comprises at least one anti-inflammatory drug that is a cyclooxygenase inhibitor.

7. The vaccine pharmaceutical composition according to claim 6 , wherein the cyclooxygenase inhibitor is at least one selected from the group consisting of cyclooxygenase non-selective inhibitors, cyclooxygenase-1 selective inhibitors, and cyclooxygenase-2 selective inhibitors.

8. The vaccine pharmaceutical composition according to claim 1 , wherein the helper peptide is PADRE.

9. The vaccine pharmaceutical composition according to claim 1 , wherein the dosage form of the vaccine pharmaceutical composition is a tape or a cream.

10. The vaccine pharmaceutical composition according to claim 1 , wherein:
the vaccine pharmaceutical composition is structured and arranged to be administered to a body surface for transdermal administration; and
a dosage form of the vaccine pharmaceutical composition is at least one selected from the group consisting of a liniment, a lotion, an aerosol, a gel, a tape, a poultice, an ointment, a plaster, and a cream.

11. A method for inducing cellular immunity in a subject comprising administering to the subject a vaccine pharmaceutical composition comprising:
an antigen;
a first cellular immunity induction promoter that is a bisphosphonate; and
a second cellular immunity induction promoter that is a helper peptide selected from the group consisting of Peptide-25, Peptide-25B, and PADRE,
wherein the administration induces a cellular immune response in the subject.

12. The method for inducing cellular immunity according to claim 11 , wherein:
the vaccine pharmaceutical composition is structured and arranged to be administered to a body surface for transdermal administration; and
a dosage form of the vaccine pharmaceutical composition is at least one selected from the group consisting of a liniment, a lotion, an aerosol, a gel, a tape, a poultice, an ointment, a plaster, and a cream.

13. The method for inducing cellular immunity according to claim 11 , wherein the first cellular immunity induction promoter that is a bisphosphonate is at least one selected from the group consisting of etidronate, clodronate, tiludronate, pamidronate, alendronate, ibandronate, neridronate, zoledronate, risedronate, and minodronate.

14. The method for inducing cellular immunity according to claim 11 , wherein the vaccine pharmaceutical composition comprises at least one of an antioxidant and an anti-inflammatory drug.

15. The method for inducing cellular immunity according to claim 14 , wherein the vaccine pharmaceutical composition comprises at least one antioxidant selected from the group consisting of sodium nitrite, ascorbic acid, sodium hydrogen sulfite, cysteine hydrochloride, citric acid hydrate, dibutylhydroxytoluene, soybean lecithin, tocopherol, sodium pyrosulfite, dibutylhydroxyanisole, 1,3-butylene glycol, benzotriazole, propyl gallate, and 2-mercaptobenzimidazole.

16. The method for inducing cellular immunity according to claim 14 , wherein the vaccine pharmaceutical composition comprises at least one anti-inflammatory drug selected from the group consisting of polyphenols, alkaloids, and phospholipase A2 inhibitors.

17. The method for inducing cellular immunity according to claim 14 , wherein the vaccine pharmaceutical composition comprises at least one anti-inflammatory drug that is a cyclooxygenase inhibitor.

18. The method for inducing cellular immunity according to claim 17 , wherein the cyclooxygenase inhibitor is at least one selected from the group consisting of cyclooxygenase non-selective inhibitors, cyclooxygenase-1 selective inhibitors, and cyclooxygenase-2 selective inhibitors.

19. The method for inducing cellular immunity according to claim 11 , comprising administering the vaccine pharmaceutical composition to a body surface of the subject.

20. The method for inducing cellular immunity according to claim 11 , wherein the helper peptide is PADRE.

Assignees

• Nitto Denko Corp

Inventors

• Shishido takuya
• Asari Daisuke
• Hori Mitsuhiko

Classifications

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/047 Primary

  having two or more hydroxy groups, e.g. sorbitol · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K31/42

  Oxazoles · CPC title